Please assess the completion status of the following clinical trial:

Trial Title: Phase 3 Study of Intranasal Carbetocin (LV-101) in Patients With Prader-Willi Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Genetically-confirmed Prader-Willi syndrome~* Provide voluntary, written informed consent (parent(s) / legal guardian(s) of participant); provide voluntary, written assent (participants, as appropriate)~* PWS Nutritional Phase 3 (hyperphagic, rarely feels full)~Exclusion Criteria:~* Living in a group home~* Genetically diagnosed Schaaf-Yang syndrome or other genetic, hormonal, or chromosomal cognitive impairment~* New food-related interventions, including environment or dietary restrictions, within 1 month of screening~* Dose of any allowed chronic concomitant medications or supplements that have not been stable for ≥3 months prior to the study or is not expected to remain stable while participating in the study; adjustments in growth hormone dose ≤10% are not exclusionary~* Presence of cardiovascular disorders, epilepsy, frequent migraines, or severe asthma~* More than 3 episodes of sinusitis in the 12 months prior to Screening Visit or presence of nasal diseases that may affect deposition of intranasal medication~* Unwilling to abstain from nasal saline, other nasal irrigation, or other intranasal medications for 2 weeks prior to the Baseline visit and during the 8-week, placebo-controlled period of the study~* Use of weight loss medication, oxytocin, carbetocin, or vasopressin in the 6 months prior to screening~* Participation in an interventional research study involving another investigational medication or device in the 6 months prior to screening or during the study~* Based on the judgment of the Investigator, is unsuitable for the study for any reason, including but not limited to unstable medical condition, inability to comply with the protocol, or other risk to subject or to the integrity of the study

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): matched placebo during first 8-weeks; prospectively randomized 1:1 to either one of the two doses of carbetocin during 56-week follow-up and optional extension periods
- 3.2 mg of LV-101 (Type: EXPERIMENTAL): 3.2 mg of LV-101 during first 8-weeks; remain on same dose during 56-week follow-up and optional extension periods
- 9.6 mg of LV-101 (Type: EXPERIMENTAL): 9.6 mg of LV-101 during first 8-weeks; remain on same dose during 56-week follow-up and optional extension periods

Based on this trial design, predict the completion outcome and termination type (if applicable).